Starting July 1, medical students who take the U.S. Medical Licensing Examination (USMLE) Step 2 Clinical Knowledge (CK) test will just have to be a little bit smarter. That's because the USMLE ...

Sanofi said two bleeding disorder treatments for both chronic and acute conditions have been approved in China, expanding its hematology offerings in the country. The French pharmaceutical company ...

Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China. Broadcom Reports Earnings After the Close Today. Analysts Expect Strong ...

Despite the considerable disease burden associated with hereditary hemorrhagic telangiectasia, no therapies are licensed for treatment. In a proof-of-concept, placebo-controlled trial, the ...

Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting 1 in 3,800 persons. HHT's hallmark symptom is chronic nosebleeds, which often ...

Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting 1 in 3,800 persons. HHT’s hallmark symptom is chronic nosebleeds, which often ...

Hereditary hemorrhagic telangiectasia (HHT) can cause recurrent, severe epistaxis, as well as anemia and reduced quality of life. The disease remains without licensed therapies worldwide. In this ...

Compared with DPP4i, use of semaglutide, tirzepatide, and liraglutide were associated with lower incidence of alcohol use disorder among patients with type 2 diabetes. Tirzepatide, semaglutide, and ...

Background: Bleeding disorders, including hemophilia, von Willebrand disease (VWD), and immune thrombocytopenia (ITP), pose significant diagnostic and therapeutic challenges due to their heterogeneous ...